)
Visual21 Nov 2025
Data center suppliers
AIM ImmunoTech (AIM) investor relations material
AIM ImmunoTech Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary17 Nov, 2025
Executive summary
Focused on developing Ampligen for cancer, viral diseases, and immune disorders, with clinical trials in pancreatic cancer, post-COVID conditions, and as a vaccine adjuvant.
Ampligen is approved in Argentina for severe CFS but not yet in the US; efforts are ongoing for broader approvals and expanded indications.
Multiple clinical trials are underway or recently completed in oncology and post-viral fatigue, with promising interim results in pancreatic and ovarian cancer.
Financial highlights
Net loss for Q3 2025 was $3.3M, down 11% from Q3 2024, and $9.8M for the nine months ended September 30, 2025, down 14% year-over-year.
Revenue for Q3 2025 was $26K, down from $35K in Q3 2024, and $67K for the nine months, down from $125K year-over-year, due to lower patient participation.
Significant one-time income: $3.04M in legal fees forgiven, recognized as other income in Q3 2025.
Operating expenses decreased: R&D down $830K and G&A down $1.28M in Q3 2025 versus Q3 2024, reflecting cost-cutting.
Cash and equivalents at September 30, 2025, were $2.3M, with total assets of $5.5M and a stockholders' deficit of $6.1M.
Outlook and guidance
Management highlights substantial doubt about the ability to continue as a going concern due to recurring losses, working capital deficit, and stockholders' equity below NYSE American listing requirements.
A plan to regain compliance with NYSE American was accepted, with a deadline of June 2026 to restore equity above $6M.
Ongoing efforts to raise capital through equity offerings, shelf registration, and an equity line of credit.
Detail the plan to achieve $6M equity by June 2026
What is the impact of AMP-270 suspension on R&D strategy?
Clarify warrant liability vs. no cash redemption
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma, Inc., is an immuno-pharmaceutical company dedicated to the research and development of therapeutics for the treatment of multiple types of cancers, viral diseases, and immune-deficiency disorders. The company's leading product candidate is Ampligen, a drug composed of macromolecular ribonucleic acid molecules aimed at treating chronic fatigue syndrome (CFS). Ampligen is also under development for various cancer types, including renal cell carcinoma, malignant melanoma, and others, as well as for conditions like Hepatitis B, HIV, COVID-19, and post-COVID conditions. Another key product is Alferon N Injection, an injectable formulation of natural alpha interferon for treating human papillomavirus (HPV) and genital warts. The company is headquartered in Ocala, Florida, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage